vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and NICOLET BANKSHARES INC (NIC). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $104.0M, roughly 1.8× NICOLET BANKSHARES INC). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 12.5%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 12.5%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Nicolet Bankshares, Inc. is a U.S. regional bank holding company based in Green Bay, Wisconsin. They are the parent company of Nicolet National Bank, the second largest Wisconsin-based bank.
AXSM vs NIC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $104.0M |
| Net Profit | — | $40.3M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | 48.3% |
| Net Margin | — | 38.8% |
| Revenue YoY | 57.4% | 12.5% |
| Net Profit YoY | — | 16.9% |
| EPS (diluted) | — | $2.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $104.0M | ||
| Q3 25 | $171.0M | $102.9M | ||
| Q2 25 | $150.0M | $95.7M | ||
| Q1 25 | $121.5M | $89.4M | ||
| Q4 24 | $118.8M | $92.4M | ||
| Q3 24 | $104.8M | $90.7M | ||
| Q2 24 | $87.2M | $85.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $40.3M | ||
| Q3 25 | $-47.2M | $41.7M | ||
| Q2 25 | $-48.0M | $36.0M | ||
| Q1 25 | $-59.4M | $32.6M | ||
| Q4 24 | $-74.9M | $34.5M | ||
| Q3 24 | $-64.6M | $32.5M | ||
| Q2 24 | $-79.3M | $29.3M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 48.3% | ||
| Q3 25 | -27.0% | 50.4% | ||
| Q2 25 | -24.5% | 46.8% | ||
| Q1 25 | -46.9% | 44.9% | ||
| Q4 24 | -61.1% | 46.8% | ||
| Q3 24 | -59.8% | 45.0% | ||
| Q2 24 | -89.5% | 43.3% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | 38.8% | ||
| Q3 25 | -27.6% | 40.6% | ||
| Q2 25 | -32.0% | 37.6% | ||
| Q1 25 | -48.9% | 36.4% | ||
| Q4 24 | -63.1% | 37.3% | ||
| Q3 24 | -61.7% | 35.8% | ||
| Q2 24 | -91.0% | 34.5% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $2.63 | ||
| Q3 25 | $-0.94 | $2.73 | ||
| Q2 25 | $-0.97 | $2.34 | ||
| Q1 25 | $-1.22 | $2.08 | ||
| Q4 24 | $-1.54 | $2.21 | ||
| Q3 24 | $-1.34 | $2.10 | ||
| Q2 24 | $-1.67 | $1.92 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | — |
| Total DebtLower is stronger | $70.0M | $134.9M |
| Stockholders' EquityBook value | — | $1.3B |
| Total Assets | $713.6M | $9.2B |
| Debt / EquityLower = less leverage | — | 0.11× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $134.9M | ||
| Q3 25 | — | $134.6M | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | — | $156.6M | ||
| Q4 24 | — | $161.4M | ||
| Q3 24 | — | $161.2M | ||
| Q2 24 | — | $162.4M |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $1.3B | ||
| Q3 25 | $73.7M | $1.2B | ||
| Q2 25 | $73.1M | $1.2B | ||
| Q1 25 | $53.2M | $1.2B | ||
| Q4 24 | $57.0M | $1.2B | ||
| Q3 24 | $92.9M | $1.1B | ||
| Q2 24 | $102.9M | $1.1B |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $9.2B | ||
| Q3 25 | $669.3M | $9.0B | ||
| Q2 25 | $639.8M | $8.9B | ||
| Q1 25 | $596.7M | $9.0B | ||
| Q4 24 | $568.5M | $8.8B | ||
| Q3 24 | $561.5M | $8.6B | ||
| Q2 24 | $548.2M | $8.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.11× | ||
| Q3 25 | — | 0.11× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.13× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $153.5M |
| Free Cash FlowOCF − Capex | — | $149.4M |
| FCF MarginFCF / Revenue | — | 143.7% |
| Capex IntensityCapex / Revenue | — | 3.9% |
| Cash ConversionOCF / Net Profit | — | 3.81× |
| TTM Free Cash FlowTrailing 4 quarters | — | $275.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $153.5M | ||
| Q3 25 | $1.0M | $45.9M | ||
| Q2 25 | $-32.4M | $38.9M | ||
| Q1 25 | $-43.4M | $41.8M | ||
| Q4 24 | $-26.2M | $133.7M | ||
| Q3 24 | $-18.6M | $39.6M | ||
| Q2 24 | $-30.1M | $37.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $149.4M | ||
| Q3 25 | $988.0K | $45.9M | ||
| Q2 25 | $-32.4M | $38.4M | ||
| Q1 25 | $-43.7M | $41.3M | ||
| Q4 24 | $-26.2M | $116.8M | ||
| Q3 24 | $-18.7M | $34.7M | ||
| Q2 24 | $-30.2M | $34.4M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 143.7% | ||
| Q3 25 | 0.6% | 44.6% | ||
| Q2 25 | -21.6% | 40.1% | ||
| Q1 25 | -36.0% | 46.2% | ||
| Q4 24 | -22.1% | 126.4% | ||
| Q3 24 | -17.9% | 38.3% | ||
| Q2 24 | -34.6% | 40.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 3.9% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.3% | 0.5% | ||
| Q4 24 | 0.0% | 18.3% | ||
| Q3 24 | 0.1% | 5.4% | ||
| Q2 24 | 0.1% | 3.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.81× | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 1.08× | ||
| Q1 25 | — | 1.28× | ||
| Q4 24 | — | 3.88× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
NIC
Segment breakdown not available.
